Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 9/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | MTOR | P42345 | 9/20 | 0.43 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14467986 | 0.90 | MRGPRX1 (0.52) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14256691 | 0.88 | LMNA (0.55) | PIK3R1PIK3CAMTORLMNAMAPT | |
| SCHEMBL14256679 | 0.87 | MAOB (0.43) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14467988 | 0.87 | MRGPRX1 (0.41) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14256743 | 0.83 | GBA1 (0.47) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14256665 | 0.83 | PIK3R1 (0.42) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14256850 | 0.83 | CCNE2 (0.44) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14256712 | 0.82 | TSHR (0.54) | PIK3R1PIK3CAMTORMRGPRX1MAPT | |
| SCHEMBL14256704 | 0.82 | TLR7 (0.43) | PIK3R1PIK3CAMTORMRGPRX1LMNA | |
| SCHEMBL14256706 | 0.82 | CHEK2 (0.52) | MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070213319-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213319-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007081978-A2 | MODULATORS OF HEPATOCYTE GROWTH FACTOR / C-MET ACTIVITY | ANGION BIOMEDICA CORPORATION (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213319-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | PIK3R1 2469/4885PIK3CA 2175/4885MTOR 795/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | PIK3R1 2591/4885PIK3CA 2245/4885MTOR 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.